Merck Company Leadership

MRK Stock  USD 130.99  0.20  0.15%   
About 83 percent of Merck's insiders are selling. The analysis of insiders' sentiment of trading Merck Company stock suggests that many insiders are terrified at this time. Merck employs about 70 K people. The company is managed by 43 executives with a total tenure of roughly 224 years, averaging almost 5.0 years of service per executive, having 1627.91 employees per reported executive.
Kenneth Frazier  Chairman
Chairman of the Board, President, Chief Executive Officer
Jennifer Zachary  President
Executive Vice President, General Counsel, Corporate Secretary

Merck's Insider Buying Vs Selling

17

 
Selling
 
Buying

Latest Trades

2024-04-10Michael C. BurgessDisposed @ 126.73
2024-02-13Joseph RomanelliDisposed 1000 @ 124.89View
2024-02-02Steven MizellDisposed 50694 @ 126.65View
2024-01-23Kathy E. ManningAcquired @ 119.86
2023-12-28Jared MoskowitzAcquired @ 108.77
2023-11-09Johannes Jacobus OosthuizenDisposed 2081 @ 102.38View
2023-11-08Richard R DelucaDisposed 43823 @ 105.03View
2023-10-24Greg StantonDisposed @ 103.02
2023-10-16Tommy TubervilleDisposed @ 104.14
2023-09-26Greg StantonAcquired @ 105.39
2023-09-21Pete RickettsDisposed @ 106.73
2023-09-13Michael C. BurgessDisposed @ 107.81
2023-09-11C. Scott FranklinDisposed @ 108.59
2023-09-08Lois FrankelDisposed @ 109.05
2023-09-06Lois FrankelDisposed @ 106.51
2023-08-14Steven MizellDisposed 4250 @ 109.01View
2023-08-03Steven MizellDisposed 4500 @ 105.49View
Monitoring Merck's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Merck's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Merck Company. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Merck's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Merck's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Merck's future performance. Based on our forecasts, it is anticipated that Merck will maintain a workforce of about 70000 employees by June 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Merck's latest congressional trading

Congressional trading in companies like Merck Company, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Merck by those in governmental positions are based on the same information available to the general public.
2024-05-02Representative Michael C BurgessAcquired Under $15KVerify
2024-03-20Representative Michael McCaulAcquired Under $15KVerify
2024-03-06Representative Ro KhannaAcquired $15K to $50KVerify
2024-02-06Representative Kathy ManningAcquired Under $15KVerify
2024-01-22Representative Jared MoskowitzAcquired Under $15KVerify
2023-11-16Senator Tommy TubervilleAcquired Under $15KVerify
2023-11-15Senator Thomas H TubervilleAcquired Under $15KVerify
2023-10-20Senator Pete RickettsAcquired $50K to $100KVerify
2022-04-08Senator Tommy TubervilleAcquired Under $15KVerify
2022-04-07Senator Thomas H TubervilleAcquired Under $15KVerify
2021-10-29Representative Gus M BilirakisAcquired Under $15KVerify
2020-04-27Representative Lois FrankelAcquired Under $15KVerify
2020-03-23Representative Mikie SherrillAcquired $1,001 -Verify

Merck Management Team Effectiveness

The company has Return on Asset of 0.1026 % which means that on every $100 spent on assets, it made $0.1026 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0531 %, implying that it generated $0.0531 on every 100 dollars invested. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.
Common Stock Shares Outstanding is expected to rise to about 2.7 B this year. Net Income Applicable To Common Shares is expected to rise to about 17.5 B this year

Merck Workforce Comparison

Merck Company is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 94,909. Merck totals roughly 70,000 in number of employees claiming about 74% of equities under Health Care industry.

Merck Profit Margins

The company has Net Profit Margin of 0.04 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.42 %, which entails that for every 100 dollars of revenue, it generated $0.42 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.7331
Slightly Up
Slightly volatile
Net Profit Margin0.00580.0061
Notably Down
Pretty Stable
Operating Profit Margin0.04730.0498
Notably Down
Slightly volatile
Pretax Profit Margin0.030.0316
Notably Down
Pretty Stable
Return On Assets0.00330.0034
Notably Down
Pretty Stable
Return On Equity0.00920.0097
Notably Down
Very volatile

Merck Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Merck insiders, such as employees or executives, is commonly permitted as long as it does not rely on Merck's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Merck insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
1.5
27
18
 729,546 
 57,702 
2024-03-01
1.2381
26
21
 595,277 
 770,979 
2023-12-01
1.2
6
5
 13,638 
 47,270 
2023-09-01
0.8333
5
6
 38,000 
 63,729 
2023-06-01
1.18
59
50
 1,178,546 
 1,031,938 
2023-03-01
1.1765
20
17
 262,301 
 433,760 
2022-12-01
0.4588
39
85
 2,658,958 
 8,578,449 
2022-09-01
2.75
11
4
 159,041 
 13,087 
2022-06-01
1.7292
83
48
 1,509,214 
 103,395 
2022-03-01
5.25
21
4
 244,707 
 1,679 
2021-12-01
0.7308
19
26
 1,045,649 
 2,081,014 
2021-09-01
4.0
4
1
 1,165 
 0.00 
2021-06-01
1.0625
51
48
 1,472,019 
 196,781 
2021-03-01
3.6
18
5
 361,717 
 4,154 
2020-12-01
0.7
7
10
 261,384 
 796,099 
2020-09-01
0.7143
5
7
 37,936 
 102,528 
2020-06-01
1.2
42
35
 1,319,129 
 150,911 
2020-03-01
4.0
20
5
 324,059 
 184,621 
2019-12-01
0.9
9
10
 22,061 
 41,948 
2019-09-01
1.75
7
4
 39,722 
 76,252 
2019-06-01
1.1892
44
37
 1,445,367 
 779,888 
2019-03-01
0.9211
35
38
 1,257,748 
 2,091,430 
2018-12-01
1.2
18
15
 1,040,955 
 1,783,786 
2018-09-01
0.9167
11
12
 639,652 
 1,305,407 
2018-06-01
2.0
42
21
 1,432,383 
 458,982 
2018-03-01
1.0625
17
16
 445,370 
 371,642 
2017-12-01
2.3333
7
3
 20,632 
 10,750 
2017-06-01
1.7143
36
21
 1,553,474 
 361,844 
2017-03-01
1.4211
27
19
 455,261 
 315,667 
2016-12-01
0.8824
15
17
 293,276 
 582,646 
2016-09-01
0.5217
12
23
 578,193 
 1,197,540 
2016-06-01
1.5185
41
27
 2,651,735 
 797,485 
2016-03-01
16.0
16
1
 232,128 
 5,500 
2015-12-01
1.0
9
9
 68,677 
 140,958 
2015-09-01
1.0
14
14
 64,343 
 100,125 
2015-06-01
1.2821
50
39
 2,716,324 
 988,397 
2015-03-01
1.5625
25
16
 405,153 
 464,088 
2014-12-01
0.75
15
20
 110,014 
 207,166 
2014-09-01
0.7143
15
21
 248,992 
 697,495 
2014-06-01
1.25
55
44
 2,250,265 
 791,303 
2014-03-01
1.1818
26
22
 326,427 
 386,720 
2013-12-01
1.2
6
5
 45,607 
 65,674 
2013-09-01
1.3333
12
9
 53,027 
 101,276 
2013-06-01
1.2727
56
44
 2,771,893 
 1,205,980 
2013-03-01
3.6
18
5
 147,652 
 45,194 
2012-12-01
0.9333
14
15
 555,297 
 1,091,760 
2012-09-01
0.8
12
15
 268,289 
 168,349 
2012-06-01
2.3182
51
22
 2,545,153 
 279,977 
2012-03-01
0.7778
21
27
 193,448 
 169,666 
2011-12-01
2.1667
13
6
 314,573 
 73,033 
2011-06-01
1.4865
55
37
 2,376,944 
 231,055 
2011-03-01
1.2963
35
27
 530,831 
 246,535 
2010-12-01
1.625
13
8
 53,246 
 85,768 
2010-09-01
5.6
28
5
 126,239 
 56,877 
2010-06-01
28.5
57
2
 2,423,858 
 63,533 
2010-03-01
1.0
41
41
 507,663 
 475,014 
2009-12-01
0.8771
264
301
 8,555,363 
 23,366,896 
2009-09-01
4.0
8
2
 23,925 
 13,635 
2009-06-01
2.7273
60
22
 2,731,491 
 652,744 
2009-03-01
3.2
16
5
 605,451 
 71,518 
2008-06-01
2.4118
41
17
 2,734,939 
 641,756 
2008-03-01
0.5
2
4
 22,674 
 58,708 
2007-12-01
4.6667
14
3
 21,656 
 7,481 
2007-09-01
0.5
1
2
 30,000 
 43,905 
2007-06-01
0.6078
31
51
 4,094,044 
 2,234,949 
2007-03-01
1.0
7
7
 178,626 
 115,256 
2006-12-01
0.8846
23
26
 522,366 
 759,412 
2006-09-01
0.5
2
4
 125,000 
 236,088 
2006-06-01
44.0
44
1
 2,985,832 
 46,350 
2006-03-01
7.5
15
2
 106,947 
 17,660 
2005-12-01
1.3333
12
9
 48,070 
 60,268 
2005-09-01
1.2
6
5
 106,290 
 206,165 
2005-06-01
7.75
31
4
 3,306,390 
 208,091 
2005-03-01
4.5
9
2
 14,727 
 18,875 
2004-12-01
1.0
7
7
 32,839 
 41,795 
2004-03-01
5.9167
71
12
 6,686,944 
 385,239 
2003-12-01
2.9167
70
24
 1,319,854 
 395,457 
2003-09-01
14.6667
44
3
 231,444 
 153,435 
2003-06-01
4.0
12
3
 25,912 
 58,292 
2003-03-01
0.6667
2
3
 246,100 
 127,090 

Merck Notable Stakeholders

A Merck stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Merck often face trade-offs trying to please all of them. Merck's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Merck's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kenneth FrazierChairman of the Board, President, Chief Executive OfficerProfile
Robert JDPresident ChairmanProfile
Cristal DowningExecutive Vice President, Chief Communications, Public Affairs OfficerProfile
Jennifer ZacharyExecutive Vice President, General Counsel, Corporate SecretaryProfile
Caroline LitchfieldChief Financial Officer, Executive Vice PresidentProfile
Julie GerberdingExecutive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population HealthProfile
Franklin ClyburnPresident, Human Health, Head of Human Health Commercial and MarketingProfile
Robert DavisExecutive Vice President, Global Services, Chief Financial OfficerProfile
Michael NallyExecutive Vice President, Chief Marketing OfficerProfile
Roger PerlmutterExecutive Vice President and Presidentident - Merck Research LaboratoriesProfile
Steven MizellExecutive Vice President, Chief Human Resources Officer, Human ResourcesProfile
Sanat ChattopadhyayExecutive Vice President and President - Merck Manufacturing DivisionProfile
Richard DeLucaExecutive Vice President and Presidentident - Merck Animal HealthProfile
Rita KarachunPrincipal Accounting Officer, Sr. VP of Fin. and Global ControllerProfile
Thomas GlocerLead Independent DirectorProfile
Christine SeidmanIndependent DirectorProfile
Kathy WardenIndependent DirectorProfile
Paul RothmanIndependent DirectorProfile
Mary CoeIndependent DirectorProfile
Peter WendellIndependent DirectorProfile
Leslie BrunLead Independent DirectorProfile
Inge ThulinIndependent DirectorProfile
Pamela CraigIndependent DirectorProfile
Patricia RussoIndependent DirectorProfile
Thomas CechIndependent DirectorProfile
Scot EbbinghausVP DevelopmentProfile
Gregory LubinieckiVP DevelopmentProfile
Arpa GarayLead - Human Health Global MarketingProfile
Dalton IIIPrincipal FinanceProfile
Michael FlemingSenior Vice President Chief Ethics and Compliance OfficerProfile
Jannie OosthuizenLead - Human Health U.S.Profile
Jennifer MauerVP CommunicationsProfile
Michael KlobucharExecutive Vice President Chief Strategy OfficerProfile
David WilliamsExecutive Vice President Chief Information Chief Information and Digital OfficerProfile
Dean LiExecutive Vice President and Presidentident, Merck Research LaboratoriesProfile
Chirfi GuindoSenior HealthProfile
Lisa LeCointeCephasSenior Vice President Chief Ethics and Compliance OfficerProfile
Joerg KoglinVice DevelopmentProfile
Stephen MayoIndependent DirectorProfile
Peter DannenbaumVice RelationsProfile
Deepak KhannaLead - Human Health InternationalProfile
Gideon BlumenthalVice AffairsProfile
Risa LavizzoMoureyIndependent DirectorProfile

About Merck Management Performance

The success or failure of an entity such as Merck Company often depends on how effective the management is. Merck management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Merck management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Merck management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.01  0.01 
Return On Capital Employed 0.04  0.04 
Return On Assets 0  0 
Return On Equity 0.01  0.01 
The data published in Merck's official financial statements usually reflect Merck's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Merck Company. For example, before you start analyzing numbers published by Merck accountants, it's critical to develop an understanding of what Merck's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Merck's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Merck's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Merck's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Merck Company. Please utilize our Beneish M Score to check the likelihood of Merck's management manipulating its earnings.

Merck Workforce Analysis

Traditionally, organizations such as Merck use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Merck within its industry.

Merck Manpower Efficiency

Return on Merck Manpower

Revenue Per Employee855.3K
Revenue Per Executive1.4B
Net Income Per Employee5.2K
Net Income Per Executive8.5M
Working Capital Per Employee92.5K
Working Capital Per Executive150.6M
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.685
Dividend Share
2.96
Earnings Share
0.91
Revenue Per Share
24.215
Quarterly Revenue Growth
0.089
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.